Make Sublingual Immunotherapy One of Your Tools in Your Practice
Coordinator of the Interest Section Forum IRSOC: Désirée Larenas Linnemann

This year the Interest Section Forum coordinators were asked by our incoming President Dr. James Li to incorporate some kind of novel format into the session, stimulating more interactive learning.

As the IS Forums are normally attended by quite a large group of people for this year’s session we chose for a Q&A format combined with discussion in small groups (3-4 people). You shall all receive a red and green card on entering the session room.

As such, we invited two highly experienced presenters with in-depth knowledge of Sublingual Immunotherapy basics, but especially the practical part of it: for the US experience Dr. Michael Blaiss and for the European experience Dr. Giovanni Passalacqua.

We moreover challenged our speakers asking them to put the message they want to deliver to you in a talk-with-questions format.

During the presentations our speakers shall ask questions to the public. We allow reply of 2-3 colleagues through the microphones, arguing in favor or against. Meanwhile you can also discuss with the colleagues sitting next to you. After this time all assistants are asked to put in their votes with the red-green card system.

We hope you all enjoy the session and most of all make this into a worthwhile learning experience that can help you in your decision making process in your practice at home, now SLIT shall be available in the US.

As this is a new format of session we would very much like to encourage you to please fill in your evaluation forms on site or online, so we can improve the session for next year. Also session content proposals are very welcome.

Some articles for suggested reading on SLIT, SLIT in US, SLIT in children and safety:


Murphy, K., et al. (2013). “A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.” J Negat Results Biomed 12(1): 10.